This company has been marked as potentially delisted and may not be actively trading. Cytori Therapeutics (CYTX) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CYTX vs. RGLS, LXRX, DOMH, FBIO, AGEN, CRIS, BOLT, SABS, MTEM, and AMGNShould you be buying Cytori Therapeutics stock or one of its competitors? The main competitors of Cytori Therapeutics include Regulus Therapeutics (RGLS), Lexicon Pharmaceuticals (LXRX), Dominari (DOMH), Fortress Biotech (FBIO), Agenus (AGEN), Curis (CRIS), Bolt Biotherapeutics (BOLT), SAB Biotherapeutics (SABS), Molecular Templates (MTEM), and Amgen (AMGN). These companies are all part of the "biotechnology" industry. Cytori Therapeutics vs. Regulus Therapeutics Lexicon Pharmaceuticals Dominari Fortress Biotech Agenus Curis Bolt Biotherapeutics SAB Biotherapeutics Molecular Templates Amgen Regulus Therapeutics (NASDAQ:RGLS) and Cytori Therapeutics (NASDAQ:CYTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, community ranking, profitability, institutional ownership and media sentiment. Do analysts prefer RGLS or CYTX? Regulus Therapeutics presently has a consensus price target of $12.75, suggesting a potential upside of 656.68%. Given Regulus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Regulus Therapeutics is more favorable than Cytori Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regulus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Cytori Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in RGLS or CYTX? Regulus Therapeutics received 52 more outperform votes than Cytori Therapeutics when rated by MarketBeat users. However, 73.67% of users gave Cytori Therapeutics an outperform vote while only 63.99% of users gave Regulus Therapeutics an outperform vote. CompanyUnderperformOutperformRegulus TherapeuticsOutperform Votes49463.99% Underperform Votes27836.01% Cytori TherapeuticsOutperform Votes44273.67% Underperform Votes15826.33% Which has more risk and volatility, RGLS or CYTX? Regulus Therapeutics has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500. Comparatively, Cytori Therapeutics has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Does the media favor RGLS or CYTX? In the previous week, Regulus Therapeutics had 3 more articles in the media than Cytori Therapeutics. MarketBeat recorded 3 mentions for Regulus Therapeutics and 0 mentions for Cytori Therapeutics. Regulus Therapeutics' average media sentiment score of 0.16 beat Cytori Therapeutics' score of 0.00 indicating that Regulus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Regulus Therapeutics Neutral Cytori Therapeutics Neutral Which has stronger valuation & earnings, RGLS or CYTX? Cytori Therapeutics has higher revenue and earnings than Regulus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRegulus TherapeuticsN/AN/A-$30.04M-$0.87-1.94Cytori Therapeutics$3.67M0.00-$12.63MN/AN/A Do insiders and institutionals hold more shares of RGLS or CYTX? 92.4% of Regulus Therapeutics shares are held by institutional investors. Comparatively, 2.6% of Cytori Therapeutics shares are held by institutional investors. 4.4% of Regulus Therapeutics shares are held by insiders. Comparatively, 0.7% of Cytori Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is RGLS or CYTX more profitable? Regulus Therapeutics has a net margin of 0.00% compared to Cytori Therapeutics' net margin of -242.60%. Regulus Therapeutics' return on equity of -53.07% beat Cytori Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Regulus TherapeuticsN/A -53.07% -48.58% Cytori Therapeutics -242.60%-272.70%-56.23% SummaryRegulus Therapeutics beats Cytori Therapeutics on 11 of the 15 factors compared between the two stocks. Remove Ads Get Cytori Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTX vs. The Competition Export to ExcelMetricCytori TherapeuticsSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.17M$3.99B$5.26B$7.12BDividend YieldN/A40.98%4.89%4.08%P/E RatioN/A27.2321.3817.51Price / SalesN/A46.42355.0688.78Price / CashN/A51.7738.1834.64Price / BookN/A5.706.233.79Net Income-$12.63M$67.02M$3.21B$247.48M Cytori Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTXCytori TherapeuticsN/AN/AN/A-59.0%$17.17M$3.67M0.0037Gap DownRGLSRegulus Therapeutics2.8819 of 5 stars$1.44+5.1%$15.00+941.7%-33.1%$95.39MN/A-1.3530LXRXLexicon Pharmaceuticals3.1218 of 5 stars$0.37+0.6%$3.67+903.5%-79.7%$89.98M$31.08M-0.49140Analyst ForecastShort Interest ↓Gap DownDOMHDominari1.402 of 5 stars$5.49+32.9%N/A+29.2%$59.91M$12.59M-1.424Upcoming EarningsFBIOFortress Biotech2.4494 of 5 stars$1.72+0.6%$21.00+1,120.9%-18.7%$47.48M$62.50M-0.56170Earnings ReportAnalyst RevisionAGENAgenus3.0084 of 5 stars$1.64+1.9%$8.75+433.5%-84.6%$41.51M$103.46M-0.15440Gap DownCRISCuris2.2694 of 5 stars$2.60-2.3%$23.00+784.6%-92.3%$22.01M$10.26M-0.3360Earnings ReportAnalyst RevisionGap DownBOLTBolt Biotherapeutics3.3636 of 5 stars$0.44-0.3%$1.25+185.6%-72.9%$16.75M$9.78M-0.2690Positive NewsSABSSAB Biotherapeutics3.0189 of 5 stars$1.60-7.0%$12.40+675.0%-74.4%$14.77M$2.24M0.00140Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap DownMTEMMolecular Templates0.9464 of 5 stars$0.00+300.0%N/A-100.0%$3,000.00$23.48M0.00260Gap UpAMGNAmgen4.2869 of 5 stars$314.38-0.5%$314.04-0.1%+9.8%$168.89B$33.42B41.6428,000News CoveragePositive News Remove Ads Related Companies and Tools Related Companies RGLS Competitors LXRX Competitors DOMH Competitors FBIO Competitors AGEN Competitors CRIS Competitors BOLT Competitors SABS Competitors MTEM Competitors AMGN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYTX) was last updated on 4/5/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytori Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytori Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CYTX Stock Free CYTX Stock Alerts